Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
US6887852B1 · kind B1 · utility
19Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2004 |
| Grant date | May 3, 2005 |
| Priority date | — |
| Expiry date | Aug 6, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/183
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing lyophilization using a mixture comprising 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits an unstable activity during lyophilization, rather than using human blood derived albumin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.